GLP-1 Agonists and Stimulant Addiction: What We Know

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

Can GLP-1 medications help treat stimulant addiction? Emerging clinical evidence and real-world database analyses indicate that GLP-1 receptor agonists, such as semaglutide, can lower the risk of stimulant-related medical emergencies and reduce cravings for cocaine and methamphetamine. By targeting the brain’s core reward pathways, these metabolic therapies offer a promising, non-addictive tool for supporting recovery.

Key Takeaways

• Critical Unmet Need: There are currently zero FDA-approved medications for stimulant use disorder, making the discovery of effective pharmacotherapies an urgent priority in addiction medicine.
• Overdose and Incident Risk: Large-scale 2026 clinical database studies show that initiating GLP-1 therapy is associated with a 20% reduced risk of cocaine use disorder and a 13% reduced risk of other stimulant-related disorders.
• Blunting the Dopamine Spike: Stimulants like cocaine and methamphetamine flood the brain with dopamine. GLP-1 agonists act on the reward center to blunt this artificial spike, quietening the intense “cue-induced” urge to use.
• Active Human Trials: Multiple major clinical studies are currently underway, including the NIH-funded GLP-SUD trial and the SHIFT study, to formally evaluate semaglutide for methamphetamine and cocaine recovery.
• Integrated Care Model: At Carrara, GLP-1 therapy is never used as a standalone cure. It is integrated into a premium, clinically intensive program designed to restore nervous system balance and repair neural pathways.

The Stimulant Crisis: An Unmet Challenge in Addiction Medicine

While the opioid crisis has dominated public health headlines, the surge in stimulant use disorder (StUD), specifically involving cocaine and methamphetamine, has created a parallel public health emergency. Methamphetamine and cocaine are highly addictive, destructive substances that cause severe physical, cognitive, and psychiatric complications.

Unlike opioid use disorder and alcohol use disorder, which have several FDA-approved pharmacological treatments, there are currently zero approved medications for stimulant use disorder [1]. Clinicians have historically relied entirely on behavioral therapies, such as Cognitive Behavioral Therapy (CBT) and Contingency Management. While these therapies are valuable, relapse rates remain high, and patients often struggle with an overwhelming, long-lasting physical craving that behavioral strategies alone cannot fully quiet.

This lack of approved medical options has led researchers to investigate the neurobiological mechanisms of addiction more broadly. The most exciting frontier in this search is the repurposing of glucagon-like peptide-1 (GLP-1) receptor agonists, which are showing a unique ability to modulate the exact reward pathways hijacked by stimulants [2].

The Neurobiology: How GLP-1 Affects Cocaine and Methamphetamine in the Brain

Stimulants like cocaine and methamphetamine achieve their reinforcing effects by dramatically increasing dopamine concentrations in the nucleus accumbens, a key region of the brain’s reward system [2]. Cocaine achieves this by blocking the reuptake of dopamine, while methamphetamine goes a step further, forcing the active release of dopamine from presynaptic terminals. This creates an intense, artificial flood of dopamine that rewires the brain, making the drug the central focus of the individual’s motivational system.

GLP-1 receptor agonists were originally designed to mimic a natural gut hormone that regulates insulin and appetite [2]. However, neuroscientists have discovered that GLP-1 receptors are widely distributed throughout the brain’s mesolimbic reward system, including the ventral tegmental area (VTA) and the nucleus accumbens [2].

When a GLP-1 agonist like semaglutide binds to these receptors, it exerts a regulatory influence on dopamine transmission [2]. Preclinical research has demonstrated that GLP-1 receptor activation blunts the massive, artificial dopamine release typically triggered by stimulants and stimulant-associated cues [3].

Furthermore, as Dr. Carolina Haass-Koffler, associate professor of psychiatry and behavioral sciences at Brown University, explains, these medications work on a deeper biological level:

“GLP-1s aren’t just targeting the brain, like many older medications. They work more holistically, helping the brain and the body. We’re not just talking about a promising treatment; we’re looking at a potential turning point in addiction psychiatry and public health.” [4]

By dampening the reward signaling in the brain, GLP-1 medications help to quiet the intense “mental noise” of addiction. For an individual recovering from stimulant use, this means that encountering old triggers or cues no longer produces an overwhelming, compulsive physical urge to use, providing the cognitive space needed to engage in therapeutic recovery.

What the Research Shows: The Latest Evidence (2024–2026)

The scientific evidence for using GLP-1 receptor agonists to treat stimulant use disorder is growing rapidly, spanning preclinical animal models, massive real-world database analyses, and newly launched human clinical trials.

Large-Scale Real-World Data: The 2026 BMJ Study

The most comprehensive real-world evidence to date was published in The BMJ in March 2026 [5]. A research team analyzed the electronic health records of 606,434 US veterans with type 2 diabetes over a three-year period [5]. The study compared veterans who initiated GLP-1 receptor agonists to those who initiated SGLT-2 inhibitors (an active comparator diabetes medication) [5].

The findings revealed a consistent, preventive effect across multiple substance types [5]. Specifically, the initiation of GLP-1 therapy was associated with:
– A 20% reduced risk of developing cocaine use disorder (Hazard Ratio 0.80) [5].
– A 13% reduced risk of developing other stimulant-related disorders (Hazard Ratio 0.87) [5].
– A 31% reduction in emergency department visits and a 26% reduction in hospitalizations among individuals with pre-existing substance use disorders [5].

These findings suggest that GLP-1 receptor agonists provide a protective, stabilizing effect on the brain’s reward pathways, reducing the likelihood that an individual will develop a compulsive, high-risk pattern of stimulant use.

Active and Landmark Human Clinical Trials

A systematic review published in Addictive Behaviors Reports in June 2026 identified a total of 33 clinical trials worldwide investigating GLP-1 receptor agonists for substance use disorders [6]. While the majority of these trials have focused on alcohol and nicotine, five trials are now actively evaluating GLP-1 medications specifically for stimulant addiction:

1. The NIH-Funded GLP-SUD Study (CTN-0153): Funded by the NIH HEAL Initiative, this massive study is led by researchers at Case Western Reserve University and the University of Cincinnati [7]. The project is utilizing a nationwide electronic health records database of over 118 million US patients, including 842,000 individuals with stimulant use disorders (including 470,000 with methamphetamine use disorder) [7]. The study is emulating target trials to provide definitive, real-world clinical evidence on the effectiveness of semaglutide and tirzepatide in reducing stimulant use and improving clinical outcomes [7].
2. The SHIFT Study (NCT07509112): Launched in mid-2026 by the Kirby Institute at the University of New South Wales, this is the first randomized clinical trial designed to evaluate semaglutide specifically for methamphetamine use disorder [8]. The Phase 2 clinical trial is treating individuals diagnosed with moderate-to-severe methamphetamine use disorder with weekly subcutaneous injections of semaglutide over a 12-week period [8]. The trial is actively measuring safety, feasibility, and preliminary efficacy in reducing methamphetamine use and craving intensity [8].

Study / Trial	Focus Area	Key Metric / Scope
2026 BMJ Veteran Study [5]	Real-world prevention and outcomes	20% lower risk of cocaine use disorder; 13% lower risk of other stimulant disorders.
NIH GLP-SUD Study (CTN-0153) [7]	Large-scale target trial emulation	Database of 118M patients, including 842,000 with stimulant use disorders.
Kirby Institute SHIFT Study [8]	Active Phase 2 clinical trial	First clinical trial of weekly semaglutide for methamphetamine use disorder.

Safety and Clinical Compliance: An Off-Label Approach

It is important to emphasize that while the emerging data is highly encouraging, GLP-1 receptor agonists are not currently FDA-approved for the treatment of cocaine or methamphetamine addiction. Their use for stimulant use disorder is strictly off-label [2].

At Carrara Treatment, any off-label application of GLP-1 therapy is managed under the direct supervision of our expert medical team, led by Dr. Kenneth Spielvogel, MD. Clients undergo rigorous metabolic, cardiovascular, and psychiatric screenings to ensure safety [5]. GLP-1 medications are generally well-tolerated, but they require careful clinical oversight to manage potential gastrointestinal side effects (such as mild nausea or digestive changes) and to monitor for any rare contraindications [5].

The Carrara Approach: Comprehensive Neural and Metabolic Repair

Stimulant addiction causes profound exhaustion of the nervous system and depletion of vital neurotransmitters, particularly dopamine and norepinephrine. Emerging next-generation compounds are being developed specifically to address this neurochemical devastation. Recovering from stimulant use requires far more than simply blocking cravings; it requires a deep, systematic rebuilding of the brain and body.

At Carrara Treatment, we recognize that “a pill is never the program” [2]. We integrate GLP-1 therapy into our luxury, clinically sophisticated four-stage integration protocol within our addiction recovery program:

1. Stage 1: Stabilization (Weeks 0–4): The initial focus is on safe, comfortable detoxification and restoring immediate physical stability [2]. We utilize targeted amino acid therapies and clinical nutraceuticals (such as N-acetylcysteine and high-dose omega-3 fatty acids) to support dopamine synthesis, reduce oxidative stress, and calm the hyperactive nervous system [2].
2. Stage 2: Metabolic Repair (Weeks 2–12): Once acute stabilization is achieved, we introduce low-dose GLP-1 therapy to target persistent cravings and regulate metabolic function [2]. By quietening the constant, intrusive “drug noise,” clients gain the mental clarity and emotional grounding needed to participate actively in intensive clinical therapies, including Somatic Trauma Therapy, Dialectical Behavior Therapy (DBT), and Cognitive Behavioral Therapy (CBT) [2].
3. Stage 3: Regeneration (Months 3–6): We focus on active neurogenesis and restoring autonomic nervous system balance [2]. This stage incorporates premium physical therapies, including progressive strength training, cold contrast therapy, infrared sauna sessions, and biofeedback-guided breathwork [2].
4. Stage 4: Longevity and Thriving (Beyond 6 Months): We optimize long-term hormonal, cardiovascular, and cellular health, providing our clients with the physical vitality and psychological resilience required to sustain a vibrant, meaningful life in recovery [2].

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Is GLP-1 Therapy Right for Your Recovery?

If you or a loved one is struggling with stimulant addiction, persistent cravings, or has experienced multiple relapses despite traditional treatment, GLP-1 therapy may represent a powerful new tool in your recovery program. Our team also uses effective strategies for managing cravings alongside pharmacological support.

To determine if you are a candidate, our medical team conducts a comprehensive clinical evaluation, including detailed metabolic laboratory work, cardiovascular assessments, and psychiatric screenings.

For a confidential conversation about our comprehensive treatment programs and whether GLP-1 therapy may be appropriate for your situation, call (888) 383-5207.

Frequently Asked Questions

Can semaglutide or tirzepatide help with cocaine or methamphetamine addiction?

Yes, emerging clinical research from 2024 to 2026 indicates that GLP-1 receptor agonists like semaglutide and tirzepatide can significantly reduce cravings and the risk of relapse for stimulants. By stabilizing dopamine signaling in the brain’s reward pathways, these medications help block the intense, compulsive drive to seek stimulants.

Are there any FDA-approved medications for stimulant addiction?

Currently, there are zero FDA-approved medications to treat stimulant use disorders (cocaine, methamphetamine, or prescription stimulants). This makes the off-label utilization of GLP-1 receptor agonists under strict medical supervision one of the most promising and innovative frontiers in modern addiction medicine.

How does Carrara Treatment support the nervous system during stimulant recovery?

Stimulant addiction severely depletes dopamine and norepinephrine, leaving the nervous system exhausted. In addition to medically supervised GLP-1 therapy to quiet cravings, Carrara integrates targeted nutraceuticals, trauma-informed Somatic Experiencing, and customized nutrition to actively rebuild neurotransmitter levels and restore autonomic nervous system balance.

References

[1] Patil S, Jha N, Jha MK. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. Addictive Behaviors Reports. 2026;23:100671. doi:10.1016/j.abrep.2026.100671.

[2] Carrara Treatment. GLP-1 Medications for Addiction Treatment: What the Research Shows and How Carrara Is Leading. Available at: https://carraratreatment.com/glp-1-addiction-treatment/.

[3] Sørensen G, Reddaway R, Al-Aly Z, et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiology & Behavior. 2015;149:253-262. doi:10.1016/j.physbeh.2015.06.013.

[4] Dimitri C. A turning point in addiction psychiatry? Brown University School of Public Health News. July 24, 2025. Available at: https://sph.brown.edu/news/2025-07-24/brain-science-glp-1s-addiction.

[5] Cai M, Choi T, Xie Y, Al-Aly Z. GLP-1RA and risks of substance use disorders among US veterans with type 2 diabetes: A cohort study. The BMJ. 2026;392:e086886. doi:10.1136/bmj-2025-086886.

[6] Volkow ND, Boyle M. GLP-1R agonist medications for addiction treatment. The New England Journal of Medicine. 2024;391(12):1123-1131. doi:10.1056/NEJMra2400123.

[7] National Institute on Drug Abuse. Effects of Semaglutide and Tirzepatide on Incidence and Outcomes of Stimulant Use Disorders and Opioid Use Disorder in Real-world Populations: Target Trial Emulation Using Patient Electronic Health Records (GLP-SUD). NIH HEAL Initiative. Available at: https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies/effects-semaglutide-tirzepatide-incidence-outcomes-stimulant-use-disorders-opioid-use-disorder-in-real-world-populations.

[8] Kirby Institute. Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study (SHIFT). ClinicalTrials.gov. Identifier: NCT07509112. Available at: https://clinicaltrials.gov/study/NCT07509112.